Literature DB >> 25523125

Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.

Z Calic1, C Cappelen-Smith2, S J Hodgkinson1, A McDougall1, R Cuganesan3, B J Brew4.   

Abstract

We report a case of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome in a multiple sclerosis (MS) patient 3.5 months after fingolimod commencement and 4.5 months after natalizumab (NTZ) cessation. Three cerebrospinal fluid analyses were required before a definitive diagnosis of progressive multifocal leukoencephalopathy was reached. Intravenous immunoglobulin (IVIG) was subsequently given as the sole MS treatment along with mirtazapine and mefloquine. There has been improvement and subsequent clinical stabilization. The notable features are the difficult timing of fingolimod commencement in the context of previous NTZ therapy, the role of repeated cerebrospinal fluid John Cunningham virus analyses in progressive multifocal leukoencephalopathy diagnosis, and the role of IVIG. Crown
Copyright © 2014. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fingolimod; Intravenous immunoglobulin; Natalizumab; PML–IRIS

Mesh:

Substances:

Year:  2014        PMID: 25523125     DOI: 10.1016/j.jocn.2014.08.016

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  17 in total

1.  Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.

Authors:  F Lauda; T Fangerau; K Javaheripour-Otto; E Pinkhardt; J Kassubek; H Tumani
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 2.  Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.

Authors:  Emanuele D'Amico; Aurora Zanghì; Carmela Leone; Hayrettin Tumani; Francesco Patti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

3.  Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.

Authors:  Eimer Maloney; Anna Molloy; Mariam Al Hussona; Luke O'Donnell; Ronan Killeen; Christopher McGuigan
Journal:  J Neurol       Date:  2016-12-30       Impact factor: 4.849

Review 4.  A review of possible therapies for multiple sclerosis.

Authors:  Hui Li; Gaojian Lian; Guang Wang; Qianmei Yin; Zehong Su
Journal:  Mol Cell Biochem       Date:  2021-04-22       Impact factor: 3.396

Review 5.  Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.

Authors:  Shitiz Sriwastava; Durgesh Chaudhary; Samiksha Srivastava; Katherine Beard; Xue Bai; Sijin Wen; Syed Hassan Khalid; Robert P Lisak
Journal:  J Neurol       Date:  2021-11-20       Impact factor: 4.849

6.  Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease.

Authors:  Ryan C Winger; Christopher T Harp; Ming-Yi Chiang; David P Sullivan; Richard L Watson; Evan W Weber; Joseph R Podojil; Stephen D Miller; William A Muller
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

7.  Not All Strokes Are Strokes An Example of Diagnostic Confirmation Bias.

Authors:  Melanie Dani; Sophie Bowen-Carpenter; Patrick J McGown
Journal:  Eur J Case Rep Intern Med       Date:  2019-01-08

8.  Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Authors:  Luisa Klotz; Berit Grützke; Maria Eveslage; Michael Deppe; Catharina C Gross; Lucienne Kirstein; Anita Posevitz-Fejfar; Tilman Schneider-Hohendorf; Nicholas Schwab; Sven G Meuth; Heinz Wiendl
Journal:  BMC Neurol       Date:  2015-06-23       Impact factor: 2.474

Review 9.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711

Review 10.  An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis.

Authors:  Neeta Garg; Thomas W Smith
Journal:  Brain Behav       Date:  2015-08-03       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.